Placental Site and Epithelioid Trophoblastic Tumours: Rare Varieties of Gestational Trophoblastic Neoplasia

2021 ◽  
pp. 113-123
Author(s):  
Shweta Tahlan ◽  
Vaishali Paliwal ◽  
Amita Maheshwari
Keyword(s):  
Gestational Trophoblastic Neoplasia ◽  
Placental Site ◽  
Trophoblastic Tumours

Results of treatment of gestational trophoblastic neoplasia in the Slovak Republic in the years 1993–2017

2021 ◽  
Vol 86 (2) ◽  
pp. 94-101
Author(s):  
Miroslav Korbeľ ◽  
◽  
Jozef Šufliarsky ◽  
Ľudovít Danihel ◽  
Zuzana Nižňanská
Keyword(s):  
Slovak Republic ◽  
Staging System ◽  
Gestational Trophoblastic Disease ◽  
World Health ◽  
Gestational Trophoblastic Neoplasia ◽  
Trophoblastic Disease ◽  
Gynecology And Obstetrics ◽  
Placental Site ◽  
Invasive Mole ◽  
Trophoblastic Tumours

Overview Objective: Gestational trophoblastic neoplasia epidemiology and treatment results in the Slovak Republic in the years 1993–2017. Methods: Retrospective analysis results of gestational trophoblastic neoplasia treatment in the Centre for gestational trophoblastic disease in the Slovak Republic in Bratislava in the years 1993–2017 according to prognostic scoring and staging system FIGO/WHO (International Federation of Gynecology and Obstetrics/World Health Organization). Results: The Centre for Gestational Trophoblastic Disease was created in the Slovak Republic in the year 1993, after the split of former Czechoslovakia. A total of 100 patients with gestational trophoblastic neoplasia were treated in this Centre in the years 1993–2017. According to prognostic scoring and staging system FIGO/ WHO, 74% patients were at a low risk and 26% of patients were at a high-risk of gestational trophoblastic neoplasia. There were 56, 2, 32 and 10% patients in stages I, II, III, and IV, respectively. The total curability and mortality rates were 96 and 4%, respectively. The curability rate 100% was achieved in stages I–III and in all placental site trophoblastic tumours, and the curability rate 60% was achieved in stage IV. In the years 1993 –2017, the incidences were 1 in 59,315 pregnancies and 1 in 42,299 deliveries for choriocarcinoma, 1 in 489,348 pregnancies and 1 in 348,965 deliveries for placental site trophoblastic tumours, 1 in 139,814 pregnancies and 1 in 99,704 deliveries for invasive mole, and 1 in 39,947 pregnancies and 1 in 28,487 deliveries for persistent gestational trophoblastic neoplasia. In the Czech Republic in the same period of time, there were treated 281 (301) patients with the curability rate 98.6% (98.7%). Conclusion: The results of the treatment of gestational trophoblastic neoplasia in the Slovak Republic are comparable with those achieved by leading centers specialized for the treatment of this disease in Europe and in the world. Early detection and centralisation of the treatment are crucial points for successful treatment, as the high curability rate of gestational trophoblastic neoplasia is achieved by effective therapy. Keywords: gestational trophoblastic neoplasia – choriocarcinoma – placental site trophoblastic tumour – epithelioid trophoblastic tumour – invasive mole – curability – mortality – reproductive outcomes

scholarly journals A Profile of Cases of Gestational Trophoblastic Neoplasia at a Large Tertiary Centre in Dubai

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Tasneem H. Rangwala ◽  
Faiza Badawi
Keyword(s):  
Gestational Trophoblastic Neoplasia ◽  
Arab Population ◽  
Hydropic Degeneration ◽  
True Incidence ◽  
Asian Populations ◽  
Tertiary Centre ◽  
Suction Curettage ◽  
Placental Site ◽  
Uterine Curettage ◽  
Cervical Preparation

Objectives. To study (1) the prevalence of different types of gestational trophoblastic neoplasia (GTN) in the local and nonlocal population of women at Al Wasl Hospital, a tertiary level referral centre for northern Emirates, (2) the safety of cervical preparation before uterine evacuation, (3) the role of repeat uterine evacuation in curing these cases, and (4) the percentage of cases ultimately requiring chemotherapy. Material and Methods. Retrospective analysis of case records of 35 women with diagnosis of gestational trophoblastic neoplasia were managed in the Department of Obstetrics and Gynecology at Al Wasl Hospital, over a 2-year period between January 2007 to December 2008. Results. 35 cases of gestational trophoblastic neoplasia were seen in a 2-year period (January 2007 to December 2008) at Al Wasl Hospital, with 7000 deliveries per year, prevalence being 1 in 400 live births. 60% cases were local Arabs. Histopathology revealed complete mole in 13 cases, partial mole in 17 cases, hydropic degeneration of villi in 4 cases, and no identifiable tissue in 1 case. No cases of choriocarcinoma or placental site trophoblastic tumour were seen during the study period. 34% cases received cervical preparation with prostaglandins prior to surgical curettage. Complications were minor. 62% were cured by primary suction curettage, 12% after second (repeat) uterine evacuation, and 25% needed single drug chemotherapy. 8% cases defaulted after primary evacuation and were lost to followup. Conclusions. Prevalence of GTN in the local Arab population is similar to other Asian populations. The majority of cases are cured by simple suction uterine curettage. Cervical preparation with prostaglandins should be done in selected cases to avoid perforation during evacuation. Second (repeat) uterine evacuation can be curative in some cases with strict selection criteria and avoid the need for chemotherapy. Regional registry of cases is needed to estimate the true incidence of this disease.

Gestational trophoblastic neoplasia

2011 ◽  
pp. 1298-1305
Author(s):  
Philip Savage ◽  
Michael J. Seckl
Keyword(s):  
Gestational Trophoblastic Disease ◽  
Gestational Trophoblastic Neoplasia ◽  
Team Working ◽  
Life Saving ◽  
Placental Site ◽  
Additional Chemotherapy ◽  
Invasive Mole ◽  
Cure Rates ◽  
Prompt Diagnosis ◽  
Hydatidiform Moles

Arising from the cells of conception, gestational trophoblastic disease (GTD) forms a spectrum of disorders from the premalignant complete and partial hydatidiform moles through to the malignant invasive mole, choriocarcinoma and very rare placental site trophoblastic tumours (PSTT). The latter three conditions are also collectively known as gestational trophoblastic neoplasia (GTN) and, although uncommon, are important to recognize as this enables life-saving therapy to be commenced. About 10% of molar pregnancies fail to die out after uterine evacuation and transform into malignant GTN that require additional chemotherapy (1). These cases are usually recognized early and therefore rarely prove difficult to treat, with cure rates approaching 100% reported in most modern series (2). However, GTN can also develop after any type of pregnancy including miscarriages, term deliveries, and medical abortions. Such patients are often not suspected of having GTN and may present late with widespread disease associated with a wide variety of medical, surgical, and gynaecological problems (3). The prompt diagnosis and early effective treatment of these women is aided by an awareness and understanding of these rare, but highly curable malignancies and good team-working between physicians, gynaecologists, pathologists, and oncologists

1169 Placental site trophoblastic tumours at charing cross 1975–1995

1995 ◽  
Vol 31 ◽  
pp. S244
Author(s):  
M. Bower ◽  
G.J.S. Rustin ◽  
R.H.J. Begent ◽  
K.D. Bagshawe ◽  
E.S. Newlands
Keyword(s):  
Placental Site ◽  
Trophoblastic Tumours

scholarly journals Genetic evidence that placental site trophoblastic tumours can originate from a hydatidiform mole or a normal conceptus

1992 ◽  
Vol 65 (3) ◽  
pp. 355-358 ◽  
Author(s):  
RA Fisher ◽  
FJ Paradinas ◽  
ES Newlands ◽  
GM Boxer
Keyword(s):  
Hydatidiform Mole ◽  
Genetic Evidence ◽  
Placental Site ◽  
Trophoblastic Tumours

Pharmacotherapy of placental site and epithelioid trophoblastic tumours

2014 ◽  
Vol 3 (1) ◽  
pp. 75-85 ◽  
Author(s):  
Fiona Taylor ◽  
Barry W Hancock
Keyword(s):  
Placental Site ◽  
Trophoblastic Tumours

Efficacy and safety of the APE (actinomycin D, cisplatin, etoposide) regimen for the management of high-risk gestational trophoblastic neoplasia.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 5028-5028
Author(s):  
Catherine Lhomme ◽  
Caroline Even ◽  
Pierre Duvillard ◽  
Patricia Pautier ◽  
Anne Floquet ◽  
...  
Keyword(s):  
Overall Survival ◽  
High Risk ◽  
Actinomycin D ◽  
Single Agent ◽  
Gestational Trophoblastic Neoplasia ◽  
Efficacy And Safety ◽  
Placental Site ◽  
Multi Agent ◽  
Figo Score

5028 Background: Patients (pts) with high risk gestational trophoblastic neoplasia (GTN) or who fail low risk single agent chemotherapy (CT) require multi agent CT to be cured. The most common regimen is etoposide (E), methotrexate and actinomycin D (A) alternating weekly with cyclophophamide and vincristine (EMA/CO). Cisplatin (P) is a very active drug but its role is controversial and usually restricted to second line. We report results of a platinum based therapy: APE. Methods: We evaluated the efficacy and safety on 103 pts treated at Institut Gustave Roussy (IGR) (n=80) or other French centers (n=23) between 1983 and 2010 with APE for high risk GTN (defined by IGR criteria [Azab, Cancer, 1988] and/or FIGO score >6). Pts with brain metastasis were excluded. Results: Efficacy was evaluated on 59 pts treated for high risk GTN in first line, and on 39 pts in >2nd line including 13 pts after multi agent CT. We excluded pts with placental site trophoblastic tumors (n=2), or with FIGO score <7 and without IGR criteria (n=3). Complete remission (CR) rate was 95%. Seven pts (7 %) relapsed and a second CR was obtained for all with surgery and/or CT. Only one patient died due to GTN, after successive CRs obtained with 3 regimens. Five year overall survival (median follow-up 6.6 years) was 98%. Toxicity was evaluated on 95 pts. No toxic death occurred. Given good efficacy and to avoid acute hematotoxicity and long-term G>1 neuro and ototoxicity APE regimen was modified as detailed in the Table (below). Long-term neuro (5 pts, G1), oto (2 pts, G1 and 2 pts, G2) and renal toxicities (1 pt, G1 ) were recorded. No long-term G2 toxicities were observed with APE3. One pt developed an AML 4 after 4cy APE and 6 cy EMA/CO. 37 pts of 40 who wished to be pregnant succeeded and all of them had at least one live birth. Conclusions: With a 98% long-term overall survival rate, an excellent reproductive outcome, and no detectable long-term toxicity, APE-3 should be regarded as an alternative standard option to EMA/CO for high-risk GTN. [Table: see text]

Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study

The Lancet ◽  
2009 ◽  
Vol 374 (9683) ◽  
pp. 48-55 ◽  
Author(s):  
Peter Schmid ◽  
Yutaka Nagai ◽  
Roshan Agarwal ◽  
Barry Hancock ◽  
Philip M Savage ◽  
...  
Keyword(s):  
Observational Study ◽  
Prognostic Markers ◽  
Retrospective Observational Study ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Placental Site ◽  
Trophoblastic Tumours

Placental site trophoblastic tumours and the concept of fertility preservation

2011 ◽  
Vol 119 (3) ◽  
pp. 369-374 ◽  
Author(s):  
S Saso ◽  
J Haddad ◽  
P Ellis ◽  
I Lindsay ◽  
NJ Sebire ◽  
...  
Keyword(s):  
Fertility Preservation ◽  
Placental Site ◽  
Trophoblastic Tumours

scholarly journals Determination of Clinical Process and Response Rate to Treatment in Patients with Gestational Trophoblastic Neoplasia (GTN) with Low and High Risk and Evaluation of Their First Pregnancy Outcome

2018 ◽  
Author(s):  
Mozaffar Aznab ◽  
Anisodowleh Nankali ◽  
Sara Daeichin
Keyword(s):  
High Risk ◽  
Treatment Protocol ◽  
High Dose Chemotherapy ◽  
Low Risk ◽  
Response To Treatment ◽  
First Year ◽  
High Dose ◽  
Gestational Trophoblastic Neoplasia ◽  
Placental Site ◽  
Risk Patients

Background: The present study was conducted to determine the response to treatment in patients with GTN, the survival rate and to investigate the outcomes of first pregnancy after chemotherapy. Materials and Methods:  The treatment protocol was based on the FIGO Staging of GTN and the Modified WHO Prognostic Scoring. Results: Complete remission was achieved with MTX in 100% of the low-risk patients and with combination therapy in 91% of the high-risk cases. Out of 27 low-risk patients, 21 had no metastasis 6 had lung metastasis, 18 preserved their fertility and conceived in the first year following the chemotherapy. Out of 3 patients who had developed invasive moles, 1 got pregnant after chemotherapy. Four of the patients with choriocarcinoma conceived in the first year following the chemotherapy. In the patient with placental site trophoblastic tumors, there was no pregnancy due to hysterectomy. Conclusion: GTN was found to be a chemosensitive condition, but more effective therapeutic protocols are therefore required.  Keywords: Gestational trophoblastic neoplasia, Choriocarcinoma, High dose chemotherapy, Pregnancy

Sign in / Sign up

Export Citation Format

Share Document